NASDAQ: GLTOGalecto Inc Stock
$23.01+0.70 (+3.14%)
Updated Dec 31, 2025
GLTO Price
$23.01
Fair Value Price
$12.19
Market Cap
$30.54M
52 Week Low
$2.01
52 Week High
$38.33
P/E
-1.9x
P/B
3.81x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.84M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.34
Operating Cash Flow
-$12M
Beta
1.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GLTO Overview
Galecto, Inc. is a clinical-stage biotechnology company developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Its research centers on the use of modulators proteins galectin-3 and LOXL-2. The company was founded in 2011 and is based in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GLTO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GLTO
Ranked#100 of 490
Ranked#100 of 490
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $17.67 | A | |
| $15.95 | A | |
| $397.65 | A |
Be the first to know about important GLTO news, forecast changes, insider trades & much more!
GLTO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GLTO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GLTO ($23.01) is overvalued by 88.81% relative to our estimate of its Fair Value price of $12.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GLTO ($23.01) is not significantly undervalued (88.81%) relative to our estimate of its Fair Value price of $12.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GLTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GLTO due diligence checks available for Premium users.
Valuation
GLTO fair value
Fair Value of GLTO stock based on Discounted Cash Flow (DCF)
Price
$23.01
Fair Value
$12.19
Overvalued by
88.81%
GLTO ($23.01) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GLTO ($23.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GLTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GLTO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.9x
Industry
146.65x
Market
43.85x
GLTO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.81x
Industry
5.25x
GLTO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GLTO's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
GLTO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.7M
Liabilities
$2.7M
Debt to equity
0.34
GLTO's short-term assets ($9.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLTO's short-term assets ($9.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLTO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GLTO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
$0.0
Financing
$0.0
GLTO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GLTO vs Biotech Stocks
Galecto Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.